Biotech Values

[DewDiligence]

Re: Eylea's tepid 2-year data

Lucentis showed a tiny, non-statisg advantage relative to Eyelea in visual acuity after 96 weeks (+7.9 letters vs +7.6 letters), while Eylea had an average of 0.5 fewer injections (4.2 vs 4.7) than Lucentis during the second year, when docs had some latitude on how often to schedule injections. There were no consequential safety differences.

All told, these results do not change my previously stated opinion that Eyelea fails to provide a meaningful improvement relative to Lucentis and hence is destined to be a modest-selling drug at best.